Prostate Cancer | Disease Landscape & Forecast | G7 | 2024
Hormonal agents are routinely used in all lines of therapy and thus dominate the treatment of prostate cancer. Next-generation hormonal treatments have expanded beyond metastatic castrate-resistant prostate cancer (mCRPC) and now dominate the treatment of nonmetastatic CRPC and hormone-sensitive prostate cancer (HSPC). The continued uptake of hormonal therapies, plus the expected label expansions of targeted agents (e.g., Janssen’s Akeega, Pfizer’s Talzenna) and radioligand therapies (Novartis’s Pluvicto), and the anticipated approvals of new therapies (e.g., Point Biopharma’s 177Lu-PNT2002, Exelixis / Genentech’s Cabometyx + Tecentriq) will drive robust market growth over the 2023-2033 forecast period.
Questions answered
- What is the estimated size of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates vary by geography, setting, and over time?
- How will the prostate cancer market evolve over the 10-year forecast period? What are the market’s drivers and constraints?
- What are interviewed experts’ insights on the current treatment options for prostate cancer?
- How will the adoption and anticipated label expansions of biomarker-driven therapies, such as PARP inhibitors and PSMA-targeted radionuclide therapies, reshape the treatment landscape for prostate cancer?
- What is the clinical and commercial potential of emerging regimens, such as Cabometyx plus Tecentriq and 177Lu-PNT2002? How are they likely to be positioned in the treatment algorithm?
Geography: United States, EU5, Japan
Primary research: 18 country-specific interviews with thought-leading medical oncologists and urologists; supported by survey data collected for this and other Clarivate research
Epidemiology: Incidence of prostate cancer by country, segmented by risk of biochemical recurrence and TNM staging; market-relevant drug-treatable and drug-treated populations
Forecast: 10-year, annualized, drug-level sales and patient share of key prostate cancer therapies through 2033, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
